NOTE 17. Income Taxes

The components of loss before income taxes is as follows:

 

 

Year ended December 31,

 

 

 

2025

 

 

2024

 

 

2023

 

Domestic operations

 

$

(34,774

)

 

$

(77,871

)

 

$

(187,763

)

Foreign operations

 

 

1,687

 

 

 

2,924

 

 

 

1,319

 

Loss before income taxes

 

$

(33,087

)

 

$

(74,947

)

 

$

(186,444

)

 

Current and deferred income taxes / (benefits) on loss from continuing operations are as follows:

 

 

Year ended December 31,

 

 

 

2025

 

 

2024

 

Current:

 

 

 

 

 

 

Federal

 

$

 

 

$

 

State and local

 

 

253

 

 

 

543

 

Foreign

 

 

2,767

 

 

 

1,778

 

Total current income taxes

 

$

3,020

 

 

$

2,321

 

Deferred:

 

 

 

 

 

 

Federal

 

$

(2,502

)

 

$

(5,410

)

State and local

 

 

(738

)

 

 

(1,968

)

Foreign

 

 

(1,358

)

 

 

(119

)

Total deferred income benefits

 

$

(4,598

)

 

$

(7,497

)

Income tax benefit

 

$

(1,578

)

 

$

(5,176

)

 

The difference between the federal statutory rate of 21% and the Company’s effective tax rate after the adoption of ASU 2023-09 is summarized as follows:

 

 

 

December 31, 2025

 

 

 

Amount

 

 

Percentage

 

U.S. federal statutory tax rate

 

$

(6,949

)

 

 

21.0

%

State and local income taxes, net of federal income tax effect (1)

 

 

(363

)

 

 

1.1

%

Foreign tax effects

 

 

 

 

 

 

United Kingdom

 

 

419

 

 

 

(1.3

)%

Other foreign jurisdictions

 

 

710

 

 

 

(2.2

)%

Research and development credits

 

 

(2,234

)

 

 

6.8

%

Change in valuation allowance

 

 

(23,159

)

 

 

70.0

%

Nontaxable or Nondeductible Items

 

 

 

 

 

 

Non-deductible officer’s compensation

 

 

31,859

 

 

 

(96.3

)%

Stock-based compensation

 

 

(12,717

)

 

 

38.4

%

Contingent consideration remeasurement

 

 

7,712

 

 

 

(23.3

)%

Non-deductible transaction cost

 

 

2,000

 

 

 

(6.0

)%

Meals and entertainment cost

 

 

1,100

 

 

 

(3.3

)%

Other

 

 

144

 

 

 

(0.4

)%

Changes in unrecognized tax benefits (2)

 

 

(100

)

 

 

0.3

%

Effective tax rate

 

$

(1,578

)

 

 

4.8

%

(1)
State taxes in California, New York and New York City made up the majority (greater than 50%) of the tax effect in this category.
(2)
Changes in unrecognized tax benefits on aggregated basis for all jurisdictions.

The difference between the federal statutory rate of 21% and the Company’s effective tax rate before the adoption of ASU 2023-09 is summarized as follows:

 

 

 

December 31, 2024

 

U.S. federal statutory rate

 

 

21.0

%

State income taxes

 

 

20.7

%

Other permanent differences

 

 

(1.2

)%

Non-deductible transaction cost

 

 

(1.3

)%

Stock-based compensation

 

 

70.2

%

Non-deductible officer’s compensation

 

 

(37.2

)%

Research and development credit

 

 

1.3

%

Change in valuation allowance

 

 

(68.7

)%

Change in state tax rates

 

 

3.0

%

Others

 

 

(0.9

)%

Effective tax rate

 

 

6.9

%

 

Significant components of the Company’s net deferred tax (liabilities) / assets are as follows:

 

 

 

Year ended December 31,

 

 

 

2025

 

 

2024

 

Deferred tax assets:

 

 

 

 

 

 

Accounts receivable reserve

 

$

1,392

 

 

$

1,178

 

Accrued payroll

 

 

11,039

 

 

 

8,201

 

Net operating loss carry forward

 

 

159,024

 

 

 

113,454

 

Stock-based compensation

 

 

27,168

 

 

 

16,218

 

Interest limitation carry forward

 

 

5,654

 

 

 

8,192

 

Tax credit

 

 

11,738

 

 

 

6,731

 

Research and development costs

 

 

44,311

 

 

 

44,519

 

Accrued expenses and others

 

 

7,878

 

 

 

3,393

 

Total deferred tax assets

 

$

268,204

 

 

$

201,886

 

Less: Valuation allowance

 

 

(237,376

)

 

 

(181,480

)

Deferred tax assets, net of valuation allowance

 

$

30,828

 

 

$

20,406

 

Deferred tax liabilities:

 

 

 

 

 

 

Fixed assets

 

$

(5,716

)

 

$

(4,661

)

Right-to-use assets

 

 

(3,522

)

 

 

(2,055

)

Intangible assets

 

 

(26,614

)

 

 

(2,234

)

Deferred state income tax and others

 

 

(11,033

)

 

 

(10,837

)

Total deferred tax liabilities

 

$

(46,885

)

 

$

(19,787

)

Net deferred tax (liabilities) / assets

 

$

(16,057

)

 

$

619

 

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, as well as operating loss and tax credit carry forwards. The recognition of a valuation allowance for deferred taxes requires management to make estimates and judgments about the Company’s future profitability which is inherently uncertain. The Company assesses all available positive and negative evidence to determine if its existing deferred tax assets are realizable on a more-likely-than-not basis. In making such an assessment, the Company considered the reversal of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operating results. The ultimate realization of a deferred tax asset is dependent on the Company’s generation of sufficient taxable income within the available net operating loss carry back and/or carryforward periods to utilize the deductible temporary differences.

A significant piece of objective negative evidence was the cumulative loss incurred in the U.S., United Kingdom, and other foreign jurisdictions over the three-year period ended December 31, 2025. Such objective evidence limits the Company’s ability to consider other subject evidence, such as the Company projections for future growth. On the basis of this evaluation, the Company continued to conclude that its U.S., United Kingdom and other foreign deferred tax assets are not realizable on a more-likely-than-not basis and that a full valuation allowance is required. The amount of deferred tax asset considered realizable, however, could be adjusted if estimates of future income during the carryforward period are reduced or increased or if objective negative evidence in the form of cumulative losses is no longer present and additional weight is given to subjective evidence such as our projections for future growth. During 2025, the Company’s valuation allowance increased by $55,896, primarily due to valuation allowances recorded with the acquisition of the Marigold’s Enterprise Business.

As of December 31, 2025, the Company had U.S. federal net operating loss carryforwards of approximately $273,444 of which $75,361 are subject to an annual limitation pursuant to IRC Section 382. Approximately, $103,081 of U.S. federal net operating loss carryforwards expire in varying amounts during 2028 to 2037, if not utilized. These net operating losses are available to offset 100% of future taxable income. The remaining $170,363 of U.S. federal net operating loss may be carried forward indefinitely but are only available to offset 80% of future taxable income. In addition, the Company had state net operating losses in various state tax jurisdictions of $24,368 (tax effected) which will expire in varying amounts during 2027 through 2045, if not utilized.

As of December 31, 2025, the Company had United Kingdom net operating loss carryforwards of approximately $273,143, primarily acquired in connection with the acquisition of the Marigold’s Enterprise Business, which may be carried forward indefinitely subject to various limitations under United Kingdom tax law.

As of December 31, 2025, the Company had U.S. federal research tax credit carryforwards of $8,643, of which $1,774 are subject to an annual limitation under IRC Section 383. These credits expire in varying amounts from 2035 to 2045, if not utilized. The Company also had state research tax credit carryforwards of $3,095 (tax effected) as of December 31, 2025, of which $2,901 may be carried forward indefinitely. The remaining $194 will expire in varying amounts from 2029 to 2040 if not utilized.

The Company plans to continue to reinvest foreign earnings indefinitely outside the U.S. If these future earnings are repatriated to the U.S., or if the Company determines that such earnings will be remitted in the foreseeable future, the Company may be required to accrue applicable withholding taxes. However, the determination of the amount of the deferred tax liability is not practicable.

A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, is as follows:

Balance as of January 1, 2024

 

$

 

Increase in tax positions for current / prior periods

 

 

675

 

Balance as of December 31, 2024

 

$

675

 

Increase in tax positions for current / prior periods

 

 

970

 

Balance as of December 31, 2025

 

$

1,645

 

 

As of December 31, 2025 and 2024, the accrued amount of interest and penalties were $192 and $173, respectively. The Company’s accounting policy is to record both accrued interest and penalties related to income tax matters in the income tax provision in the accompanying consolidated statements of operations and comprehensive loss.

Cash taxes paid in accordance with the adoption of ASU 2023-09 were as follows:

 

 

 

Year ended December 31, 2025

 

Federal

 

$

 

State and local

 

 

964

 

Foreign

 

 

2,098

 

Total

 

$

3,062

 

 

 

Income taxes paid (net of refunds) exceeded 5% of total income taxes paid (net of refunds) in the following jurisdictions:

 

 

 

Year ended December 31, 2025

 

State and local

 

 

 

New York (1)

 

$

361

 

New York City (1)

 

 

218

 

Texas

 

 

256

 

 

 

 

Foreign

 

 

 

India

 

$

1,373

 

Germany

 

 

292

 

Czech Republic

 

 

235

 

(1)
The New York State and New York City cash taxes paid are related to capital taxes and are not included in the Company’s income tax provision but are disclosed as part of the Company’s income taxes paid on the consolidated statements of cash flows.

The Company, or one of its subsidiaries, files its tax returns in the U.S. and certain state and foreign income tax jurisdictions with varying statutes of limitations. The earliest years’ tax returns filed by the Company that are still subject to examination by the tax authorities in the major jurisdictions are as follows:

 

Jurisdiction

 

Tax Year

U.S.

 

2022

Belgium

 

2022

France

 

2022

India

 

2023

United Kingdom

 

2022

Historical Timeline

Fiscal YearFiled
2025Feb 25, 2026Showing above
2024Feb 26, 2025
2023Feb 28, 2024
2022Feb 24, 2023
2021Feb 25, 2022

About Income Taxes Disclosures

The income tax disclosure reveals how much a company actually pays in taxes versus what the statutory rate would predict. Analysts focus on the effective tax rate (ETR) reconciliation, which breaks down every item driving the gap between the 21% federal rate and the company's reported ETR — including R&D credits, foreign rate differentials, and state taxes. Deferred tax assets (DTAs) and their valuation allowances signal management's confidence in future profitability: a rising allowance suggests the company doubts it can use accumulated tax benefits. Uncertain tax benefit (UTB) reserves quantify exposure to IRS challenges on aggressive positions.

Key signals to watch: sudden ETR drops without clear operational reasons, large increases in valuation allowances, growing UTB balances, and significant unremitted foreign earnings. Post-TCJA, pay attention to GILTI and BEAT provisions that affect multinational tax structures. Compare the cash taxes paid (from the cash flow statement) against the income tax provision to gauge earnings quality.